David A. Siegel Maxcyte, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Maxcyte, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 27,400 shares of MXCT stock, worth $101,928. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,400
Previous 22,500
21.78%
Holding current value
$101,928
Previous $105,000
8.57%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding MXCT
# of Institutions
126Shares Held
62MCall Options Held
2.4KPut Options Held
2.1K-
Black Rock Inc. New York, NY7.23MShares$26.9 Million0.0% of portfolio
-
Cadian Capital Management, LP New York, NY6.56MShares$24.4 Million0.98% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny6.17MShares$23 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.35MShares$19.9 Million0.0% of portfolio
-
Vitruvian Partners LLP5.04MShares$18.8 Million6.7% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $378M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...